HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 09, September 2019 – Healthy Ageing — How Science is chipping in       » Officials in China make progress in development of new drugs       » The Science of Healthy Ageing       » Thailand Medtech landscape - Customer to Innovator       » China-Thailand Joint Research Institute on Medicine Launched in Bangkok      
BIOBOARD - REST OF THE WORLD
Evasion of immunodeficiency viruses by our ancestors
CryoEM reveals structural effect of mutation that made humans, but not apes, immune to SIV

The simian immunodeficiency virus (SIV) has plagued monkeys and apes for centuries, and it still devastates primate groups in Africa.

Human evolution from these early primates have allowed us to pick up a mutation that made us immune from SIV – at least until the early 20th century, when the virus evolved to counter our defences, giving rise to the human immunodeficiency virus (HIV) and an AIDS pandemic that today affects an estimated 38 million people worldwide.

University of California, Berkeley, researchers have now discovered how that long-ago human mutation interfered with SIV infection, a finding that could provide clues for the development of new therapies to thwart HIV and similar viral infections.

"The main importance for this paper is that it tells us what was one of the last major barriers before the crossover to humans happened," said James Hurley, a UC Berkeley professor of molecular and cell biology. "The current paper is an archaeological look at how this happened."

This genetic mutation interfered with the ability of an SIV protein to tightly bind two human proteins and send them for destruction within the cell, instead of fighting the virus. The researchers used cryo-electron microscopy (cryoEM), to determine the structure of this protein complex and discovered that the mutation so effectively disrupted the protein binding sites that it took SIV a long time to find a work-around.

Though the SIV virus — in this case, from a monkey called the sooty mangabey, the source of the less virulent HIV-2 strain in humans — differs in several ways from the HIV strains that afflict humans, the findings could pinpoint targets for drugs as researchers look for "functional" cures for AIDS. These would be one-time treatments that prevent flare-ups of the disease, even if the virus remains in the body.

SIV and HIV, which are lentiviruses, are hard to root out the body because they insert their DNA into the genomes of host cells, where it sits like a ticking time bomb, ready at any moment to revive, take over the host cell's machinery to makes copies of itself and send out thousands of these copies — called virions — to infect other cells.

These virions are formed when the newly copied viral DNA wraps itself in a piece of the host cell's membrane and buds off, safely ensconced in a bubble until it can cause reinfection.

Because budding is an important step in the spread of many viruses, primates long ago evolved natural defences, including proteins on the surface of cells that staple the budding virions to the cell and prevent them from leaving. As they accumulate, the immune system recognizes these unbudded virions as abnormal and destroys the whole cell, virus and all.

In monkey, ape and human cells, the staple is called tetherin, because it tethers the budding virion to the cell membrane.

Over time, SIV evolved a countermeasure that exploits another normal cell function: its recycling system. Cells have ways to remove proteins sitting on the surface, through which cells constantly take up and recycle tetherin if there's no indication it is needed to fight an invading virus. It does this by dimpling the membrane inward to form a little bubble inside the cell, capturing tetherin and other surface proteins in this vesicle and then digesting all the contents, including tetherin.

SIV's countermeasure was to produce a protein, called Nef, that boosts the recycling of tetherin, even during an infection. This enables virions to bud off and search for new victims.

Hurley and project scientist Xuefeng "Snow" Ren found that Nef forms a tight wedge between tetherin and a protein in the vesicle called AP-2, preventing tetherin from escaping the vesicle and dooming it to recycling.

"Nef is a bridge between AP2 and tetherin to recruit them into endocytosis, dragging the tetherin into the vesicle," Ren said. "So, it tricks our own cells' machinery for getting rid of stuff we don't want into getting rid of stuff the virus doesn't want."

The five amino acids that humans lost in the tetherin protein — the mutation that gave humans immunity against SIV — loosened the binding between tetherin, Nef and AP-2, which allowed tetherin to escape recycling. This blocked the crossover of zoonotic virus transmission, Ren said, because the structural rearrangement was so extensive that SIV couldn't fix it by simple mutations in Nef.

Some variants of SIV did eventually find a way around this hurdle, however. At some point, a few SIVs acquired a second protein, Vpu, to do what Nef also did -- wedge itself between proteins to cement connections helpful to the virus. At some point, perhaps a hundred years ago, this strain of SIV moved into humans from chimpanzees, and a slight mutation in Vpu reignited the recycling of tetherin in humans, unleashing what we know today as group M HIV-1, the most virulent form of HIV worldwide.

Next up, Hurley, Ren and their colleagues plan to use cryoEM to determine the structure of the three-protein complex in gorilla variants of SIV, which evolved into the O strain of HIV-1, a less virulent strain that originated in the African country of Cameroon.

Reference:

Cosmo Z. Buffalo, Christina M. Stürzel, Elena Heusinger, Dorota Kmiec, Frank Kirchhoff, James H. Hurley, and Xuefeng Ren. (2019) Structural Basis for Tetherin Antagonism as a Barrier to Zoonotic Lentiviral Transmission. Cell Host & Microbe. Cell Press ISSN 1931-3128

 

Click here for the complete issue.

NEWS CRUNCH  
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
news Medial Fair Thailand opened on 11th September 2019 with a focus on future-proofing Thailand's healthcare industry to meet the challenges and opportunities of the next decade
news Biofuel Producers and Users to Convene in Singapore for Global Biofuels Summit
news Philip Morris International opens artificial intelligence competition to develop improved strategies for medical diagnosis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy